Literature DB >> 29903517

Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population.

Laroussi Mohamed-Salem1, Juan José Santos-Mateo2, Juan Sanchez-Serna2, Álvaro Hernández-Vicente3, Rafael Reyes-Marle1, María I Castellón Sánchez1, María Antonia Claver-Valderas4, Emiliano Gonzalez-Vioque5, Francisco J Haro-Del Moral6, Pablo García-Pavía7, Domingo A Pascual-Figal8.   

Abstract

BACKGROUND: Myocardial uptake of bone tracers has emerged as useful tool for the early detection of transthyretin amyloidosis (ATTR). The prevalence of wild-type ATTR (ATTRwt) in individuals remains to be established.
METHODS: All whole body bone scans performed in individuals ≥ 75 years with no previous clinical suspicion of ATTR were revised in a population-based university hospital over a 7-year period (1509 studies corresponding to 1114 patients; 80.5 ± 4.1 years, 65% males). Positive cardiac uptake was defined according to Perugini score as grade 2 or 3. Heart failure (HF) hospitalizations during the follow-up were obtained from regional administrative databases.
RESULTS: Thirty-one patients ≥ 75 years (2.78%) showed cardiac uptake; compared with those without uptake, these patients were older (85 ± 5 vs. 80 ± 4, p < 0.001) and predominantly males (90% vs. 64%, p = 0.005). The prevalence of cardiac uptake was 3.88% in males and 0.77% in females, and increased with age, reaching 13.9% in males≥85 years (2.7% among females). The estimated prevalence for the European standard population ≥ 75 years was 4.15% in males, 1.03% in females and 2.59% in the general population. HF hospitalizations rates were 14% in patients without uptake and 29% in those with cardiac uptake (p = 0.034). After adjusting for age and gender, cardiac uptake was associated with a higher risk of HF hospitalization (OR 2.60, 95%CI 1.09-5.74, p = 0.022).
CONCLUSIONS: Myocardial uptake in bone scan is very prevalent with ageing, mainly affects males and is associated with an increased risk of HF hospitalization. These findings reinforce ATTRwt as a relevant cause of HF in the elderly.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyloidosis; Heart failure; Scintigraphy; Transthyretin; Wild-type

Mesh:

Substances:

Year:  2018        PMID: 29903517     DOI: 10.1016/j.ijcard.2018.06.006

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  20 in total

1.  State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.

Authors:  Vasvi Singh; Rodney Falk; Marcelo F Di Carli; Marie Kijewski; Claudio Rapezzi; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2018-12-19       Impact factor: 5.952

Review 2.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Sabahat Bokhari; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Martha Grogan; Arnt V Kristen; Isabelle Lousada; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Ronald Witteles; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2019-09-04       Impact factor: 8.790

3.  Amyloidosis of the Brain and Heart: Two Sides of the Same Coin?

Authors:  Chris L Schaich; Mathew S Maurer; Neelesh K Nadkarni
Journal:  JACC Heart Fail       Date:  2019-02       Impact factor: 12.035

Review 4.  Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/CT, and Amyloid-Targeting PET.

Authors:  Jin Chul Paeng; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-01-07

Review 5.  Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.

Authors:  Vasiliki Bistola; John Parissis; Emmanouil Foukarakis; Pipitsa N Valsamaki; Aris Anastasakis; Georgios Koutsis; Georgios Efthimiadis; Efstathios Kastritis
Journal:  Heart Fail Rev       Date:  2021-01-15       Impact factor: 4.214

Review 6.  Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.

Authors:  Jan M Griffin; Mathew S Maurer
Journal:  Trends Cardiovasc Med       Date:  2019-12-17       Impact factor: 6.677

7.  Incidental cardiac uptake in bone scintigraphy: increased importance and association with cardiac amyloidosis.

Authors:  Francis T Delaney; Philip Dempsey; Ivan Welaratne; Bryan Buckley; Donagh O'Sullivan; Martin O'Connell
Journal:  BJR Case Rep       Date:  2021-01-19

8.  Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.

Authors:  Timothy J Poterucha; Pierre Elias; Sabahat Bokhari; Andrew J Einstein; Albert DeLuca; Mona Kinkhabwala; Lynne L Johnson; Kathleen R Flaherty; Sunil E Saith; Jan M Griffin; Adler Perotte; Mathew S Maurer
Journal:  JACC Cardiovasc Imaging       Date:  2020-11-18

Review 9.  Future Perspectives.

Authors:  Angela Dispenzieri; Giampaolo Merlini
Journal:  Hematol Oncol Clin North Am       Date:  2020-12       Impact factor: 3.722

10.  Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications.

Authors:  Jorge Penalver; Maxwell Ambrosino; Hee D Jeon; Akanksha Agrawal; Napatt Kanjanahattakij; Marie Pitteloud; Jessica Stempel; Aman Amanullah
Journal:  Curr Cardiol Rev       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.